- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05586425
Neuroplastic Adaptations in Youth at High Risk for Developing Psychopathology
Neuroplastic Adaptations in Youth at High Risk for Developing Psychopathology: A Randomized Controlled Trial Modelling Feasibility and Clinical Improvement Following ERS Training With Changes in Brain Connectivity and Anatomy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Maiko Schneider, MD/PhD
- Phone Number: 39159 905-522-1155
- Email: mschneid@stjoes.ca
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Between the ages of 17 and 24 years, inclusive
- Difficulties in Emotion Regulation Scale score >96 at baseline
- Able to provide written informed consent and communicate in English
Exclusion Criteria:
- Diagnosis of an active substance use disorder (SUD)
- Diagnosis of an organic brain disorder
- Lifetime history of a psychotic disorder (e.g., bipolar affective disorder, schizophrenia, schizoaffective disorder, etc.)
- Active PTSD symptoms
- Currently using antidepressants, only if the last adjustment in dose was within 3 months of beginning the study
- Has received standard DBT treatment in the past 2 years
- MRI contraindications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Emotion Regulation Skills + Treatment as Usual
Emotion Regulation Skills (ERS), a version of Dialectical Behaviour Therapy Skills Training, is a type of skills-focused therapy for individuals who experience severe emotion dysregulation.
|
ERS has been updated to be friendlier to youth and involves learning skills for how to: (1) be more present in the moment, (2) effectively manage and respond to emotional experiences, (3) communicate your needs to others, and (4) increase your ability to tolerate distress.
|
|
Active Comparator: Treatment as Usual
Treatment as Usual entails psychiatric medication management, psychiatric management, individual support from peer mentors, drop-in activity groups, etc.
|
Treatment as Usual entails psychiatric medication management, psychiatric management, individual support from peer mentors, drop-in activity groups, etc.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recruitment Rate (Feasibility Threshold)
Time Frame: 14 weeks
|
Assessed by the total number of participants recruited from one site during the recruitment period (i.e., Is one site sufficient for recruitment or will the larger study require additional sites or strategies to recruit the necessary sample size? Is it plausible to recruit the required number of TGD individuals?) |
14 weeks
|
|
Eligibility Participants (Feasibility Threshold)
Time Frame: 14 weeks
|
Assessed by changes in the baseline number of participants contacted to the number of failed screening assessments (i.e., Are the criteria too narrow? What is the rate of individuals being contacted to participate in the study, but failing screening assessments?) |
14 weeks
|
|
Length of Completion of Procedures (Feasibility Threshold)
Time Frame: 14 weeks
|
Assessed by comparing the actual time required per session to the anticipated 3-hour allotment for assessments (i.e., Is the actual time required per study visit different from what is anticipated?) |
14 weeks
|
|
Location Logistics (Feasibility Threshold)
Time Frame: 14 weeks
|
Assessed by subjective evaluation and feedback from the research assistant (i.e., Are there unforeseen difficulties due to the Imaging Research Centre being located in a different place than the YWC?) |
14 weeks
|
|
Attrition Rate (Feasibility Threshold)
Time Frame: 14 weeks
|
Assessed by changes from the baseline number of participants to those retained at 14 weeks (i.e., What percentage of individuals drop out of ERS and the study?)
|
14 weeks
|
|
Intervention Attendance Rates (Feasibility Threshold)
Time Frame: 14 weeks
|
Assessed by comparing the number of sessions attended to the total number of sessions allocated (i.e., On average, how many ERS sessions do individuals attend?)
|
14 weeks
|
|
Burdensomeness of Study Procedures (Feasibility Threshold)
Time Frame: 14 weeks
|
Assessed by subjective evaluation provided by study participants (i.e., Are study procedures too lengthy or onerous for participants?) |
14 weeks
|
|
Research Impact on the Youth Wellness Centre (YWC)
Time Frame: 14 weeks
|
Assessed by a subjective review and feedback from the clinical team, up to 14 weeks (i.e., How do YWC staff perceive the impact of research procedures on their own logistics?) |
14 weeks
|
|
Communication between Clinical and Research staff
Time Frame: 14 weeks
|
assessed by subjective review and feedback from the clinical team, up to 14 weeks
|
14 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Emotion Dysregulation and other relevant symptoms/conditions
Time Frame: 14 weeks
|
Changes in the Difficulties in Emotion Regulation Scale (DERS) from baseline to 14 weeks; compared within (pre and post) and between groups (ERS and TAU) The DERS is a 36-item, self-report measure of emotion dysregulation with a 5-point Likert scale (1 = "almost never" to 5 = "almost always). Improvement of 20% or greater on the DERS will be considered significant clinical improvement. |
14 weeks
|
|
Resting-state functional connectivity (rs-FC)
Time Frame: 14 weeks
|
Changes in blood-oxygen-level-dependent (BOLD) signal (measured by fMRI) from baseline to 14 weeks; compared within (pre and post) and between groups (ERS and TAU)
|
14 weeks
|
|
Emotion Dysregulation and brain connectivity between limbic and prefrontal brain areas
Time Frame: 14 weeks
|
Changes in the DERS scale compared to changes in blood-oxygen-level-dependent (BOLD) signal (measured by fMRI) in the limbic and prefrontal brain regions from baseline to 14 weeks; compared within (pre and post) and between groups (ERS and TAU)
|
14 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Maiko Schneider, MD/PhD, McMaster University
Publications and helpful links
General Publications
- O'Neill A, D'Souza A, Samson AC, Carballedo A, Kerskens C, Frodl T. Dysregulation between emotion and theory of mind networks in borderline personality disorder. Psychiatry Res. 2015 Jan 30;231(1):25-32. doi: 10.1016/j.pscychresns.2014.11.002. Epub 2014 Nov 13.
- Gratz KL, Moore KE, Tull MT. The role of emotion dysregulation in the presence, associated difficulties, and treatment of borderline personality disorder. Personal Disord. 2016 Oct;7(4):344-353. doi: 10.1037/per0000198.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 13517
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.